ResMed [RMD] vs Hologic [HOLX] Detailed Stock Comparison

ResMed

NYSE
Loading...

Hologic

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: ResMed wins in 13 metrics, Hologic wins in 6 metrics, with 0 ties. ResMed appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricResMedHologicBetter
P/E Ratio (TTM)28.4127.86Hologic
Price-to-Book Ratio6.653.08Hologic
Debt-to-Equity Ratio14.2752.09ResMed
PEG Ratio0.945.78ResMed
EV/EBITDA21.1412.47Hologic
Profit Margin (TTM)27.22%13.79%ResMed
Operating Margin (TTM)33.87%25.48%ResMed
EBITDA Margin (TTM)33.87%25.48%ResMed
Return on Equity25.86%11.38%ResMed
Return on Assets (TTM)14.02%6.69%ResMed
Free Cash Flow (TTM)$1.65B$1.15BResMed
Dividend Yield0.63%N/AN/A
1-Year Return18.23%-15.37%ResMed
Price-to-Sales Ratio (TTM)7.713.70Hologic
Enterprise Value$39.33B$15.57BResMed
EV/Revenue Ratio7.643.86Hologic
Gross Profit Margin (TTM)60.84%56.32%ResMed
Revenue per Share (TTM)$35$18ResMed
Earnings per Share (Diluted)$9.54$2.41ResMed
Beta (Stock Volatility)0.850.57Hologic
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

ResMed vs Hologic Stock Performance Analysis

Loading Price Chart...

ResMed
Hologic
ResMed Stock Overview | Hologic Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
ResMed2.14%3.49%2.08%8.11%24.05%21.08%
Hologic1.30%3.22%1.95%4.00%12.14%-5.34%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
ResMed18.23%24.38%57.07%409.47%747.03%1,327.45%
Hologic-15.37%6.51%-2.13%82.16%322.59%379.59%

News Based Sentiment: ResMed vs Hologic

ResMed

News based Sentiment: POSITIVE

ResMed experienced a strong September, marked by positive Q4 earnings, increased dividend payouts, and multiple analyst upgrades, including a 'strong-buy' rating from UBS and a 'Buy' rating with a $330 target from Citigroup. While insider selling occurred, the overall narrative is positive, supported by robust financial performance and strategic initiatives.

View ResMed News Sentiment Analysis

Hologic

News based Sentiment: NEUTRAL

The month's news for Hologic paints a picture of stability rather than dramatic growth. While the stock outperformed the S&P 500 slightly and analyst estimates are trending upward, the overall sentiment is neutral due to the 'Hold' rating and modest gains. The valuation metrics suggest potential value, but don't indicate a strong buy signal.

View Hologic News Sentiment Analysis

Performance & Financial Health Analysis: ResMed vs Hologic

MetricRMDHOLX
Market Information
Market Cap i$40.08B$14.94B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i840,5303,267,260
90 Day Avg. Volume i936,6632,018,787
Last Close$276.64$67.91
52 Week Range$199.92 - $293.81$51.90 - $84.39
% from 52W High-5.84%-19.53%
All-Time High$301.34 (Sep 06, 2021)$87.88 (May 01, 2023)
% from All-Time High-8.20%-22.72%
Growth Metrics
Quarterly Revenue Growth0.10%0.01%
Quarterly Earnings Growth0.30%0.00%
Financial Health
Profit Margin (TTM) i0.27%0.14%
Operating Margin (TTM) i0.34%0.25%
Return on Equity (TTM) i0.26%0.11%
Debt to Equity (MRQ) i14.2752.09
Cash & Liquidity
Book Value per Share (MRQ)$40.77$21.79
Cash per Share (MRQ)$8.26$8.47
Operating Cash Flow (TTM) i$1.75B$1.07B
Levered Free Cash Flow (TTM) i$1.21B$760.11M
Dividends
Last 12-Month Dividend Yield i0.63%N/A
Last 12-Month Dividend i$1.59N/A

Valuation & Enterprise Metrics Analysis: ResMed vs Hologic

MetricRMDHOLX
Price Ratios
P/E Ratio (TTM) i28.4127.86
Forward P/E i26.3414.23
PEG Ratio i0.945.78
Price to Sales (TTM) i7.713.70
Price to Book (MRQ) i6.653.08
Market Capitalization
Market Capitalization i$40.08B$14.94B
Enterprise Value i$39.33B$15.57B
Enterprise Value Metrics
Enterprise to Revenue i7.643.86
Enterprise to EBITDA i21.1412.47
Risk & Other Metrics
Beta i0.850.57
Book Value per Share (MRQ) i$40.77$21.79

Financial Statements Comparison: ResMed vs Hologic

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)RMDHOLX
Revenue/Sales i$1.35B$1.01B
Cost of Goods Sold i$527.93M$628.00M
Gross Profit i$820.07M$377.30M
Research & Development i$86.44M$61.50M
Operating Income (EBIT) i$456.57M$37.90M
EBITDA i$532.89M$121.70M
Pre-Tax Income i$458.05M$-28.50M
Income Tax i$78.35M$-11.10M
Net Income (Profit) i$379.71M$-17.40M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)RMDHOLX
Cash & Equivalents i$1.21B$1.43B
Total Current Assets i$3.51B$3.21B
Total Current Liabilities i$1.02B$989.70M
Long-Term Debt i$811.41M$2.47B
Total Shareholders Equity i$5.97B$4.62B
Retained Earnings i$6.08B$3.03B
Property, Plant & Equipment i$288.62M$939.80M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)RMDHOLX
Operating Cash Flow i$441.40M$28.40M
Capital Expenditures i$-30.59M$-24.70M
Free Cash Flow i$504.99M$129.20M
Debt Repayment i$-5.00M$-10.20M
Common Stock Repurchase i$-100.01M$-200.00M

Short Interest & Institutional Ownership Analysis

MetricRMDHOLX
Shares Short i8.65M3.11M
Short Ratio i8.772.03
Short % of Float i0.07%0.02%
Average Daily Volume (10 Day) i840,5303,267,260
Average Daily Volume (90 Day) i936,6632,018,787
Shares Outstanding i146.39M231.73M
Float Shares i145.48M220.32M
% Held by Insiders i0.01%0.01%
% Held by Institutions i0.65%1.01%

Dividend Analysis & Yield Comparison: ResMed vs Hologic

MetricRMDHOLX
Last 12-Month Dividend i$1.59N/A
Last 12-Month Dividend Yield i0.63%N/A
3-Year Avg Annual Dividend i$1.60N/A
3-Year Avg Dividend Yield i0.23%N/A
3-Year Total Dividends i$4.79N/A
Ex-Dividend DateFeb 13, 2025N/A